Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects.
NCT01751269 is registered in ClinicalTrials.gov with Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects.
- Lead sponsor
- Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 31, 2012
- Completion date
- July 31, 2013
- Enrollment
- 80 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
bacterial infections, healthy volunteers